US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PPD, Inc.

47.28

0.0000

Volume:- -

Turnover:- -

Market Cap:16.61B

PE:47.03

High:47.28

Open:47.28

Low:47.28

Close:47.28

Loading ...

Overview Company News Filings

Press Release: Fortrea Names Anshul Thakral Chief Executive Officer

‘Humble’ stockpicker is mystery buyer of Bronte’s trophy house

The Australian Financial Review

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

Henna 101: We ask an artist all about this traditional art form and what you need to know before getting one

Press Release: Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up

FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

Press Release: Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PPD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PPD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPD\",,,,,undefined,":{"symbol":"PPD","market":"US","secType":"STK","nameCN":"PPD, Inc.","latestPrice":47.28,"timestamp":1751486400000,"preClose":47.28,"halted":3,"volume":0,"delay":0,"floatShares":117802105,"shares":351394547,"eps":1.005366,"marketStatus":"Halted","change":0,"latestTime":"07-02 16:00:00 EDT","open":47.28,"high":47.28,"low":47.28,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.005366,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751529600000},"marketStatusCode":5,"adr":0,"listingDate":1580965200000,"exchange":"NASDAQ","adjPreClose":47.28,"volumeRatio":0,"impliedVol":0.1524,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPD\",,,,,undefined,":{"symbol":"PPD","floatShares":117802105,"roa":"6.39%","roe":"-27.30%","lyrEps":0.352171,"shares":351394547,"dividePrice":0,"high":47.28,"amplitude":0,"preClose":47.28,"low":47.28,"week52Low":47.28,"pbRate":"-39.14","week52High":47.28,"institutionHeld":0,"latestPrice":47.28,"eps":1.005366,"divideRate":0,"volume":0,"delay":0,"ttmEps":1.005366,"open":47.28,"prevYearClose":47.28,"prevWeekClose":47.28,"prevMonthClose":47.28,"prevQuarterClose":47.28,"fiveDayClose":47.28,"twentyDayClose":47.28,"sixtyDayClose":47.28},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542853786","title":"Press Release: Fortrea Names Anshul Thakral Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2542853786","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542853786?lang=en_us&edition=fundamental","pubTime":"2025-06-12 04:10","pubTimestamp":1749672600,"startTime":"0","endTime":"0","summary":"DURHAM, N.C., June 11, 2025  -- Fortrea  , a leading global contract research organization , today announced that Fortrea's Board of Directors  named Anshul Thakral as Fortrea's CEO, effective August 4, 2025. He was also appointed to serve as a director on the Company's Board, effective as of that date. Thakral succeeds Interim CEO, Peter M. Neupert, who will remain as chairman of the board.Thakral joins Fortrea from Launch Therapeutics, a company he co-founded at which he served as CEO. Previously, he held several executive leadership roles at PPD, a leading CRO, including chief commercial officer and executive vice president of Peri- and Post-Approval Services. He led PPD Biotech, which contributed to PPD's growth. Prior to PPD, Thakral ran the global life sciences business unit at Gerson Lehrman Group and served as an Associate Principal at McKinsey & Company in the healthcare practice. He currently serves on the board of directors of TriNetX, Saama Technologies and Orsini Specialty","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPD","BK6512","BK4530","BK6071","BK4121","AWI.SI","FTRE","BK4561"],"gpt_icon":0},{"id":"2534250362","title":"‘Humble’ stockpicker is mystery buyer of Bronte’s trophy house","url":"https://stock-news.laohu8.com/highlight/detail?id=2534250362","media":"The Australian Financial Review","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534250362?lang=en_us&edition=fundamental","pubTime":"2025-05-12 16:40","pubTimestamp":1747039200,"startTime":"0","endTime":"0","summary":"Over the weekend, news came through that hundreds of spectators had shown up for the auction of a trophy home on Sydney’s eastern suburbs, in one of its best beachside locations.The 841-square-metre house in Bronte  was eventually sold for $23.5 million – a suburb record for an auction. The buyers were described as a “local family”, with Alexander Phillips from PPD saying it was “very unusual” to have three other parties bidding over $20 million, and that it “shows there’s still plenty of people out there willing to spend their money”.Loading...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.afr.com/rear-window/humble-stockpicker-is-mystery-buyer-of-bronte-s-trophy-house-20250512-p5lyhr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"afr_stock","symbols":["BK4561","BK4530","BK4121","PPD"],"gpt_icon":0},{"id":"2531794241","title":"Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2531794241","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531794241?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:05","pubTimestamp":1745957100,"startTime":"0","endTime":"0","summary":"Achieved $13.8 million in ZURZUVAE  collaboration revenue in the first quarter of 2025 , representing a 21% increase from the fourth quarter. Sustained growth in shipments to women with postpartum depression; Greater than 3,000 shipments in first quarter of 2025 . Cash, cash equivalents, and marketable securities of $424 million as of March 31, 2025; Cash runway expected to support operations to mid-2027. CAMBRIDGE, Mass., April 29, 2025----Sage Therapeutics, Inc. , today reported business highlights and financial results for the first quarter ended March 31, 2025.\"We delivered strong growth in revenue and shipments of ZURZUVAE during the first quarter of 2025 through the team’s disciplined execution and unwavering commitment to bringing ZURZUVAE to more women with postpartum depression,\" said Barry Greene, Chief Executive Officer at Sage Therapeutics. \"We remain focused on establishing ZURZUVAE as the standard of care for women with postpartum depression and driving our business strat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-therapeutics-announces-first-quarter-200500915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GABA","SAGE","BK4135","BK4139","BK4561","BK4563","BK4081","CNS","PPD","BK4211","PAM","BK4530","BK4121"],"gpt_icon":0},{"id":"2523653387","title":"Henna 101: We ask an artist all about this traditional art form and what you need to know before getting one","url":"https://stock-news.laohu8.com/highlight/detail?id=2523653387","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523653387?lang=en_us&edition=fundamental","pubTime":"2025-03-29 06:40","pubTimestamp":1743201642,"startTime":"0","endTime":"0","summary":"What is natural henna made of? How do you avoid imitation henna that can potentially cause chemical burns? Find out from one of Singapore's OG henna artists Syra Gulam.","market":"nz","thumbnail":"https://dam.mediacorp.sg/image/upload/s--TBVwetmO--/c_crop,h_2129,w_2838,x_0,y_1/c_fill,g_auto,h_622,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/03/27/5_0.jpg?itok=pZPrY2Q1","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--TBVwetmO--/c_crop,h_2129,w_2838,x_0,y_1/c_fill,g_auto,h_622,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/03/27/5_0.jpg?itok=pZPrY2Q1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/living/henna-malay-indian-culture-weddings-deepavali-eid-5028291","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["5GC.SI","BK4530","PPD","BK4561","BK4121"],"gpt_icon":0},{"id":"2519383562","title":"Press Release: Lipocine Announces Financial Results for the Full Year Ended December 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2519383562","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519383562?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:00","pubTimestamp":1741867200,"startTime":"0","endTime":"0","summary":"SALT LAKE CITY, March 13, 2025 /PRNewswire/ -- Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the year ended December 31, 2024, and provided a corporate update.-- LPCN 1154 is an oral formulation of the neuroactive steroid brexanolone. that Lipocine is developing for the rapid treatment of postpartum. -- Lipocine held a meeting with the U.S. Food and Drug Administration . in the first quarter of 2025 to discuss the NDA submission package for. LPCN 1154  as a treatment for PPD. In the meeting,Lipocine was advised that the FDA believes that, in addition to the. previously completed PK bridge data, a safety and efficacy study of oral. LPCN 1154 in the target population will be required for 505 NDA. submission. Based on observed comparable exposure of LPCN 1154 and the. reference drug in the PK bridge study, the company is initiating a phase. 3 safety a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPD","BK4121","BK4135","BK4604","KOL","BK4588","BK4007","03160","BK4555","BK4561","TM","CNS","BK4585","GCC","BK4099","BK4530","UAE","LPCN"],"gpt_icon":0},{"id":"2516569505","title":"Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516569505","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516569505?lang=en_us&edition=fundamental","pubTime":"2025-03-02 04:19","pubTimestamp":1740860399,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025.In this article, we are going to take a look at where Sage Therapeutics, Inc.  stands against the other psychedelic stocks.The Therapeutic Potential and Investment Boom in Psychedelic Medicine. Psilocybin  is the most widely used psychedelic drug in the United States, with an estimated 8 million American adults using it in 2023, according to a survey conducted by RAND Corporation. Around 12% of respondents reported lifetime use, and 3.1% used it in the past year. LSD use has also risen significantly, particularly among individuals aged 18-25, with usage increasing from 0.9% in 2002 to 4% in 2019. The LSD market is projected to grow from $145.9 million in 2024 to $265.7 million by 2034. MDMA, although not providing specific usage data, remains popular, especially in research for PTSD treatment. Ketamine has gained attention for its depression","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-therapeutics-inc-sage-among-201959349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","NVIW.SI","MNQmain","BK4139",".IXIC","QID","BK4121","SAGE","SQQQ","QLD","USAW.SI","NQmain","PSQ","TSYW.SI","BK4530","USJW.SI","BK4561","PPD"],"gpt_icon":1},{"id":"2514780569","title":"GH Research Reports Full Year 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514780569","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514780569?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025. Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK. Full response to the IND hold on track for submission in mid-2025. Cash, cash equivalents, other financial assets and marketable securities of $182.6 million as of December 31, 2024. Net cash proceeds of an additional $139.8 million from public offering received in February 2025. DUBLIN, Feb. 27, 2025  -- GH Research PLC , a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2024, and provided updates on its business.As previously announced, our Investigational New Drug Application  for GH001 administered using our proprietary aerosol delivery device","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gh-research-reports-full-2024-120000403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4561","BK4585","BK4539","GH","BK4196","GHRS","BK4121","BK4535","BK4588","BK4530","PPD","BK4551","BK4007"],"gpt_icon":0},{"id":"2509273678","title":"Lipocine Receives Updated Regulatory Guidance on LPCN 1154","url":"https://stock-news.laohu8.com/highlight/detail?id=2509273678","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509273678?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:00","pubTimestamp":1738846800,"startTime":"0","endTime":"0","summary":"SALT LAKE CITY, Feb. 6, 2025 /PRNewswire/ -- Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced receipt of revised regulatory guidance for LPCN 1154 which the Company is developing for postpartum depression  treatment. As previously disclosed, the Company was scheduled to meet with the U.S. Food and Drug Administration  in Q1 2025 to discuss the NDA submission package of LPCN 1154. Following the meeting, the Company was advised that the Division believes, in addition to the previously completed PK bridge data, an efficacy and safety study of oral LPCN 1154 in the target populationwillbe required for 505 NDA submission.Lipocine remains committed to advancing a rapid relief treatment for postpartum depression. Based on the guidance received and observed comparable exposure of LPCN 1154 and the reference drug in the completed PK bridge study, Lipocine is planning next steps tow","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lipocine-receives-updated-regulatory-guidance-130000094.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lipocine-receives-updated-regulatory-guidance-130000094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LPCN","BK4561","PPD","BK4530","BK4121","BK4007"],"gpt_icon":0},{"id":"2507542821","title":"SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2507542821","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507542821?lang=en_us&edition=fundamental","pubTime":"2025-01-29 00:54","pubTimestamp":1738083240,"startTime":"0","endTime":"0","summary":"Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen BIIB to acquire the remaining shares of SAGE.Per Sage Therapeutics, the BIIB offer significantly undervalues the company and is not in the best interest of shareholders.SAGE’s board of directors has now started exploring strategic alternatives and evaluating other options to maximize its shareholders’ value.Shares of SAGE were up 4.8% on Jan. 27 following the news announcement.In the past year, the stock has plunged 72% compared with the industry’s decline of 12.4%.Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Jan. 10.Biogen currently owns a 10.2% stake in SAGE, per a SEC filing by the company.Some better-ranked stocks in the biotech sector are Harmony Biosciences ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-rejects-biogens-offer-buy-165400180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIIB","BK4585","LU0320765992.SGD","PPD","SAGE","ET","BK4581","BK4196","LU0889565916.HKD","BK4561","IE00B19Z9P08.USD","BK4144","BK4530","LU0234570918.USD","BK4532","BK4590","BK4533","BK4007","IE00B19Z9Z06.USD","BK4588","IE00B894F039.SGD","CSTL","MCI","BK4139","HRMY","BK4121","LU0109394709.USD"],"gpt_icon":0},{"id":"2503650859","title":"FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi","url":"https://stock-news.laohu8.com/highlight/detail?id=2503650859","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503650859?lang=en_us&edition=fundamental","pubTime":"2025-01-14 22:04","pubTimestamp":1736863460,"startTime":"0","endTime":"0","summary":"On Monday, the FDA accepted Eisai Co., Ltd.  and Biogen Inc’s  Biologics License Application  for lecanemab-irmb  subcutaneous autoinjector  for weekly maintenance dosing.Leqembi is indicated for Alzheimer’s disease in patients with Mild Cognitive Impairment or mild dementia stage of the disease.A Prescription Drug User Fee Act  action date is August 31, 2025.The BLA is based on data from the Clarity AD  open-label extension  and modeling of observed data.Also Read: Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown. If the FDA approves Leqembi subcutaneous maintenance dosing, Leqembi will be the only treatment for AD that can be administered subcutaneously at home using an autoinjector.The injection process is expected to take, on average, 15 seconds. As part of the SC-AI 360 mg weekly maintenance regimen, patients who have completed the biweekly intravenous  initiation phase, the exact period under discussion with the FDA, would receive weekly doses expected to maintai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-review-under-skin-weekly-140420876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0109394709.USD","BIIB","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0234570918.USD","BK4561","IE00B894F039.SGD","BK4530","BK4585","AAIC","BK4588","LU0889565916.HKD","BK4533","LU0320765992.SGD","PPD","BK4532","BK4110","BK4121","BK4139"],"gpt_icon":0},{"id":"2503555448","title":"Biogen Offers to Buy Remaining Stake in Sage Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2503555448","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503555448?lang=en_us&edition=fundamental","pubTime":"2025-01-14 04:00","pubTimestamp":1736798400,"startTime":"0","endTime":"0","summary":"Sage Therapeutics  said Biogen  has made an unsolicited offer to acquire the rest of SAGE shares.Biogen currently owns a 10.2% stake in Sage Therapeutics; SAGE board members will review the offer.Sage Therapeutics SAGE announced that its partner Biogen BIIB has made an unsolicited, non-binding proposal offer to acquire the SAGE shares that it does not already own for $7.22per share. The offer price represents a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Friday.At present, Biogen owns a 10.2% stake in SAGE, per a SEC filing by the company. Sage Therapeutics’ board will review and evaluate the offer and will come to a final decision.SAGE’s stock was up 46% in after-hours trading on Friday in response to the news while Biogen was down slightly.Biogen’s shares have declined 40%, while Sage Therapeutics’ stock has been down 79.1% in the past year, compared with a decrease of 15.9% for the industry.In September, Biogen terminated its rights under the collaboration and lic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biogen-offers-buy-remaining-stake-200000531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","BK4581","IE00B894F039.SGD","BK4139","PPD","BK4585","MCI","ABVC","PBYI","BK4530","BK4561","BK4588","LU0234570918.USD","BK4533","BK4196","BK4121","LU0109394709.USD","BK4532","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","CSTL","LU0320765992.SGD","BIIB","LU0889565916.HKD","SAGE","BK4590","ET"],"gpt_icon":0},{"id":"2503258330","title":"Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503258330","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503258330?lang=en_us&edition=fundamental","pubTime":"2025-01-13 22:38","pubTimestamp":1736779121,"startTime":"0","endTime":"0","summary":"On Friday, Sage Therapeutics Inc.  confirmed thatBiogen Inc. submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares ofSage Therapeuticsnot already owned by Biogen for$7.22per share.The Sage Board of Directors will carefully review and evaluate Biogen’s proposal.Also Read: After Failed Alzheimer’s Study, Sage Therapeutics’ Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder. In November 2020, Biogen andSage Therapeutics executed a global collaboration and license agreement to jointly develop and commercialize zuranolone  for major depressive disorder , postpartum depression  and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.Over the last five years, Sage stock has slumped 90%.In October last year, Sage Therapeutics announced a strategic reorganization of its business operations to support the ongoing launch of Zurzuvae in postpartum depression.The company said the reorganization was i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-depression-focused-sage-therapeutics-143841762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","IE00B19Z9P08.USD","BK4139","BIIB","IE00B19Z9Z06.USD","LU0320765992.SGD","BK4588","LU0889565916.HKD","PPD","BK4121","LU0234570918.USD","BK4533","SAGE","LU0109394709.USD","BK4530","BK4561","IE00B894F039.SGD","BK4585"],"gpt_icon":0},{"id":"2502528748","title":"GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents","url":"https://stock-news.laohu8.com/highlight/detail?id=2502528748","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502528748?lang=en_us&edition=fundamental","pubTime":"2025-01-10 20:00","pubTimestamp":1736510400,"startTime":"0","endTime":"0","summary":"Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points(p<0.0001, n=10) and 100% of patients in remission at Day 8Primary endpoint met ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/10/3007557/0/en/GH-Research-Announces-Primary-Endpoint-Met-in-Two-Phase-2a-POC-Trials-with-GH001-and-Completion-of-All-FDA-Requests-to-Address-IND-Hold-with-No-Findings-of-Respiratory-Toxicity-in-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4535","BK4585","IDR","BK4530","BK4168","BK4561","GH","BK4121","PPD","BK4196","BK4588"],"gpt_icon":0},{"id":"2501723047","title":"Press Release: Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501723047","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501723047?lang=en_us&edition=fundamental","pubTime":"2025-01-08 20:05","pubTimestamp":1736337900,"startTime":"0","endTime":"0","summary":"BOSTON and LONDON, Jan. 08, 2025  -- Centessa Pharmaceuticals plc , a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer . Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.\"Orexin agonists are one of the most exciting emerging areas of therapeutic science, and Centessa's potential best-in-class OX2R agonists represent an extraordinary opportunity to address unmet patient needs across multiple therapeutic areas,\" said Stephen Kanes, MD PhD, Chief Medical Officer. \"With Phase 2a clinical studies of ORX750 now underway, it's an exciting time to be joining Centessa. I look forward to working with the team and contributing to the success of the Company's growing OX2R agonist franchise.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","CNTA","IH","BK4108","BK4565","BK4022","BK4526","BK4548","BK4232","BK4571","CMO","LU0359202008.SGD","BK4561","01698","LU1023057109.AUD","BK4531","BK4509","BK4535","IE00BYQNZ168.SGD","TME","LU0359201612.USD","BK4139","BK4552","PPD","BK4196","LU2039709279.SGD","IE00BYTNYN87.SGD","IE00B12V2V27.USD","BK4085","BK4510","BK4563","BK4539","MD","R","BK4530","SG9999011746.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPD\",params:#limit:5,,,undefined,":[{"date":"2021-10-28","symbol":"PPD","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2021/09","expectedEps":0.35,"defaultRemindTime":1635451200000,"name":null,"time":"Post Market","dateTimestamp":1635393600000,"actualEps":null},{"market":"US","date":"2021-07-28","symbol":"PPD","fiscalQuarterEnding":"2021/06","expectedEps":0.34,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1627444800000,"reportTimeType":"post","actualEps":0.36},{"market":"US","date":"2021-04-27","symbol":"PPD","fiscalQuarterEnding":"2021/03","expectedEps":0.31,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1619496000000,"reportTimeType":"post","actualEps":0.33},{"market":"US","date":"2021-02-23","symbol":"PPD","fiscalQuarterEnding":"2020/12","expectedEps":0.34,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1614056400000,"reportTimeType":"post","actualEps":0.38},{"market":"US","date":"2020-10-27","symbol":"PPD","fiscalQuarterEnding":"2020/09","expectedEps":0.15,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1603771200000,"reportTimeType":"post","actualEps":0.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PPD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PPD","date":"2021-12-09","current":45.63553,"percent":0.035165,"low":45.461791,"twenty":76.447997,"median":144.910788,"eighty":183.913548,"high":257.573166,"avg":133.670985,"sd":56.331588,"marketCap":16613934182},"quantilePoints":[{"date":"2020-07-02","current":199.030288,"twenty":160.976351,"median":197.919628,"eighty":211.11624,"marketCap":9369947892},{"date":"2020-07-10","current":215.394013,"twenty":161.967692,"median":198.51198,"eighty":211.239057,"marketCap":10140319352},{"date":"2020-07-17","current":223.020546,"twenty":163.702539,"median":198.632745,"eighty":211.721431,"marketCap":10499361254},{"date":"2020-07-24","current":220.280918,"twenty":164.19821,"median":199.104332,"eighty":215.695509,"marketCap":10370385037},{"date":"2020-07-31","current":217.467245,"twenty":164.518938,"median":199.474552,"eighty":216.697187,"marketCap":10237922976},{"date":"2020-08-07","current":142.465689,"twenty":163.702539,"median":199.43753,"eighty":217.667984,"marketCap":11147940180},{"date":"2020-08-14","current":138.010852,"twenty":159.853802,"median":199.030288,"eighty":216.697187,"marketCap":10799349180},{"date":"2020-08-21","current":141.88656,"twenty":144.353742,"median":198.609385,"eighty":216.326967,"marketCap":11102623350},{"date":"2020-08-28","current":151.419912,"twenty":145.041995,"median":198.437936,"eighty":215.651083,"marketCap":11848608090},{"date":"2020-09-04","current":143.757592,"twenty":145.041995,"median":197.512386,"eighty":215.413854,"marketCap":11249031570},{"date":"2020-09-11","current":149.905267,"twenty":145.883354,"median":195.957462,"eighty":214.994175,"marketCap":11730087150},{"date":"2020-09-18","current":150.796235,"twenty":145.883354,"median":195.425464,"eighty":214.683191,"marketCap":11799805350},{"date":"2020-09-25","current":150.306202,"twenty":146.626507,"median":194.735736,"eighty":213.631766,"marketCap":11761460340},{"date":"2020-10-02","current":158.770393,"twenty":146.920526,"median":193.847207,"eighty":212.284165,"marketCap":12423783240},{"date":"2020-10-09","current":164.517133,"twenty":147.009623,"median":187.255354,"eighty":211.751048,"marketCap":12873465630},{"date":"2020-10-16","current":162.601553,"twenty":147.624391,"median":174.578137,"eighty":211.553847,"marketCap":12723571500},{"date":"2020-10-23","current":158.057619,"twenty":148.381713,"median":174.104334,"eighty":211.29476,"marketCap":12368008680},{"date":"2020-10-30","current":163.434526,"twenty":149.121215,"median":169.111181,"eighty":211.133018,"marketCap":11496638283},{"date":"2020-11-06","current":178.14761,"twenty":149.620158,"median":170.204572,"eighty":210.477491,"marketCap":12531615452},{"date":"2020-11-13","current":172.033727,"twenty":149.83399,"median":169.150758,"eighty":209.109098,"marketCap":12101540479},{"date":"2020-11-20","current":167.758979,"twenty":150.012183,"median":169.130969,"eighty":208.316353,"marketCap":11800837653},{"date":"2020-11-27","current":174.32022,"twenty":150.10128,"median":168.892503,"eighty":208.15251,"marketCap":12262381526},{"date":"2020-12-04","current":173.22668,"twenty":150.199286,"median":170.34371,"eighty":207.974804,"marketCap":12185457547},{"date":"2020-12-11","current":171.089306,"twenty":150.306202,"median":171.0396,"eighty":207.78229,"marketCap":12035106134},{"date":"2020-12-18","current":173.723743,"twenty":150.413118,"median":171.089306,"eighty":207.426879,"marketCap":12220422992},{"date":"2020-12-24","current":173.22668,"twenty":150.582403,"median":172.033727,"eighty":206.843646,"marketCap":12185457547},{"date":"2020-12-31","current":167.162503,"twenty":150.618041,"median":171.297964,"eighty":206.110064,"marketCap":11758879119},{"date":"2021-01-08","current":180.831753,"twenty":150.65368,"median":171.665845,"eighty":206.110064,"marketCap":12720428854},{"date":"2021-01-15","current":178.644673,"twenty":150.92097,"median":172.630203,"eighty":206.056518,"marketCap":12566580897},{"date":"2021-01-22","current":174.270513,"twenty":151.419912,"median":173.22668,"eighty":205.842336,"marketCap":12258884981},{"date":"2021-01-29","current":160.800088,"twenty":151.689814,"median":173.176973,"eighty":204.80572,"marketCap":11311321425},{"date":"2021-02-05","current":176.209061,"twenty":151.738319,"median":173.22668,"eighty":204.716867,"marketCap":12395250217},{"date":"2021-02-12","current":185.007088,"twenty":151.98132,"median":173.350945,"eighty":204.228177,"marketCap":13014138591},{"date":"2021-02-19","current":181.627055,"twenty":152.177234,"median":173.524918,"eighty":203.69506,"marketCap":12776373566},{"date":"2021-02-26","current":80.259419,"twenty":151.932341,"median":173.574624,"eighty":203.546972,"marketCap":12335150360},{"date":"2021-03-05","current":76.447997,"twenty":150.618041,"median":173.350945,"eighty":203.176752,"marketCap":11749369125},{"date":"2021-03-12","current":83.291552,"twenty":150.128009,"median":173.22668,"eighty":203.102708,"marketCap":12801161908},{"date":"2021-03-19","current":84.5684,"twenty":149.673616,"median":172.729616,"eighty":202.806532,"marketCap":12997402003},{"date":"2021-03-26","current":84.04398,"twenty":147.009623,"median":172.133139,"eighty":202.495547,"marketCap":12916803393},{"date":"2021-04-01","current":86.278465,"twenty":145.883354,"median":171.193635,"eighty":202.258606,"marketCap":13260223559},{"date":"2021-04-09","current":86.278465,"twenty":143.401205,"median":170.989893,"eighty":202.006857,"marketCap":13260223559},{"date":"2021-04-16","current":104.427952,"twenty":142.519147,"median":169.772087,"eighty":201.829151,"marketCap":16049636337},{"date":"2021-04-23","current":105.51948,"twenty":141.565812,"median":169.150758,"eighty":201.72549,"marketCap":16217394416},{"date":"2021-04-30","current":75.253588,"twenty":138.919639,"median":168.688612,"eighty":201.296034,"marketCap":16210375419},{"date":"2021-05-07","current":75.194137,"twenty":130.652966,"median":168.382254,"eighty":200.451933,"marketCap":16197568982},{"date":"2021-05-14","current":75.096376,"twenty":123.305377,"median":168.082071,"eighty":199.844772,"marketCap":16176510387},{"date":"2021-05-21","current":75.16155,"twenty":112.050736,"median":167.653326,"eighty":199.563405,"marketCap":16190549450},{"date":"2021-05-28","current":75.224773,"twenty":105.533181,"median":167.311622,"eighty":199.430126,"marketCap":16204168444},{"date":"2021-06-04","current":75.43672,"twenty":105.419007,"median":166.934112,"eighty":199.311655,"marketCap":16249823882},{"date":"2021-06-11","current":75.84431,"twenty":102.108165,"median":165.820431,"eighty":199.119141,"marketCap":16337622801},{"date":"2021-06-18","current":75.469327,"twenty":87.73316,"median":164.805363,"eighty":198.911818,"marketCap":16256847795},{"date":"2021-06-25","current":75.338899,"twenty":87.327305,"median":164.684214,"eighty":198.713839,"marketCap":16228752141},{"date":"2021-07-02","current":75.126952,"twenty":86.360548,"median":164.294391,"eighty":198.623401,"marketCap":16183096704},{"date":"2021-07-09","current":74.670451,"twenty":85.982054,"median":164.081581,"eighty":198.586024,"marketCap":16084761915},{"date":"2021-07-16","current":74.80088,"twenty":85.275227,"median":163.75981,"eighty":198.586024,"marketCap":16112857569},{"date":"2021-07-23","current":74.996523,"twenty":83.49676,"median":163.447972,"eighty":198.437936,"marketCap":16155001050},{"date":"2021-07-30","current":79.332562,"twenty":81.302924,"median":163.202956,"eighty":198.363892,"marketCap":16223588160},{"date":"2021-08-06","current":79.024087,"twenty":79.912546,"median":162.539811,"eighty":197.919628,"marketCap":16160504904},{"date":"2021-08-13","current":79.195879,"twenty":79.402029,"median":161.06767,"eighty":197.105144,"marketCap":16195636436},{"date":"2021-08-20","current":79.075625,"twenty":79.230237,"median":160.596876,"eighty":196.142572,"marketCap":16171044363},{"date":"2021-08-27","current":79.625358,"twenty":79.240544,"median":160.531082,"eighty":195.92044,"marketCap":16283465267},{"date":"2021-09-03","current":80.243807,"twenty":79.293488,"median":160.195941,"eighty":195.639073,"marketCap":16409938784},{"date":"2021-09-10","current":80.089195,"twenty":79.327546,"median":158.503103,"eighty":195.500318,"marketCap":16378320404},{"date":"2021-09-17","current":80.226628,"twenty":79.346605,"median":157.864962,"eighty":195.416131,"marketCap":16406425630},{"date":"2021-09-24","current":80.449957,"twenty":79.381414,"median":156.587523,"eighty":195.135574,"marketCap":16452096622},{"date":"2021-10-01","current":80.38124,"twenty":79.402029,"median":153.135024,"eighty":194.735736,"marketCap":16438044009},{"date":"2021-10-08","current":80.570211,"twenty":79.422644,"median":152.266331,"eighty":194.528412,"marketCap":16476688695},{"date":"2021-10-15","current":80.638927,"twenty":79.460438,"median":151.811078,"eighty":194.069339,"marketCap":16490741308},{"date":"2021-10-22","current":80.810719,"twenty":79.505103,"median":150.796235,"eighty":192.277474,"marketCap":16525872840},{"date":"2021-10-29","current":81.085638,"twenty":79.563513,"median":150.439848,"eighty":189.586929,"marketCap":16582094100},{"date":"2021-11-05","current":45.645182,"twenty":79.402029,"median":150.128009,"eighty":189.00348,"marketCap":16617448127},{"date":"2021-11-12","current":45.606574,"twenty":79.27813,"median":149.81617,"eighty":188.4392,"marketCap":16603392345},{"date":"2021-11-19","current":45.606574,"twenty":79.209029,"median":148.613364,"eighty":187.358628,"marketCap":16603392345},{"date":"2021-11-26","current":45.703095,"twenty":79.034395,"median":147.009623,"eighty":186.392604,"marketCap":16638531800},{"date":"2021-12-03","current":45.54866,"twenty":78.97255,"median":146.586413,"eighty":184.78838,"marketCap":16582308672},{"date":"2021-12-09","current":45.63553,"twenty":76.447997,"median":144.910788,"eighty":183.913548,"marketCap":16613934182}],"updateTime":1751476317361}}}